Stelfonta (Tigilanol Tiglate) Injection for Dogs, 1mg/mL

Supplied By: Virbac (VINV-VC01-0101)


SKU
073416


Unit of
Measure 2mL


Pack
Type Vial


Case
Qty 10

Login
{{promo.PromoName}}

{{promo.PromoText}}

{{promo.StartDate | date : 'MM/dd/yyyy'}} - {{promo.EndDate | date : 'MM/dd/yyyy'}}
Jul- 2024 Jun- 2024 May- 2024 Apr- 2024 Mar- 2024 Feb- 2024 Jan- 2024 Dec- 2023 Nov- 2023 Oct- 2023 Sep- 2023 Aug- 2023 Jul- 2023
{{purchaseHistoryItem}}


SKU 073416


Size 2mL

Case
Qty 10

Purchase History

Jul- 2024 {{productPurchaseHistory['073416'][0]}} Dec- 2023 {{productPurchaseHistory['073416'][0+7]}}
Jun- 2024 {{productPurchaseHistory['073416'][1]}} Nov- 2023 {{productPurchaseHistory['073416'][1+7]}}
May- 2024 {{productPurchaseHistory['073416'][2]}} Oct- 2023 {{productPurchaseHistory['073416'][2+7]}}
Apr- 2024 {{productPurchaseHistory['073416'][3]}} Sep- 2023 {{productPurchaseHistory['073416'][3+7]}}
Mar- 2024 {{productPurchaseHistory['073416'][4]}} Aug- 2023 {{productPurchaseHistory['073416'][4+7]}}
Feb- 2024 {{productPurchaseHistory['073416'][5]}} Jul- 2023 {{productPurchaseHistory['073416'][5+7]}}
Jan- 2024 {{productPurchaseHistory['073416'][6]}}
{{promo.PromoName }}

{{promo.PromoText}}

{{promo.StartDate | date : 'MM/dd/yyyy'}} - {{promo.EndDate | date : 'MM/dd/yyyy'}}
Login

Compare Products

{{compareProd.sku}}

{{compareProd.desc}}

{{compareMessage}}

Product Description

Stelfonta®
injection is an FDA-approved local treatment for non-metastatic Mast Cell Tumors (MCTs). Indicated for use in dogs for the treatment of non-metastatic cutaneous mast cell tumors, or non-metastatic subcutaneous mast cell tumors located at or distal to the elbow or the hock. For intratumoral injection in dogs only.



Human
Safety: Accidental self-injection of STELFONTA® may cause severe wound formation. To decrease the risk of accidental self-injection, sedation of the dog may be necessary.

Features & Benefits

  • Treat MCTs with a single intratumoral injection, without surgery or anesthesia
  • Starts working within 2 hours, with tumors typically destroyed by day 7
  • Easy healing with more than half of tumor sites fully healed by day 28
  • 75% complete response with just one treatment
  • See Virbac for data on file regarding results